Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Spliceosome mutations (SRSF2, SF3B1, U2AF1, ZRSR2), are encountered in ∼50% of secondary acute myeloid leukemia cases (sAML) and define a molecular subgroup with outcomes similar to sAML in de novo AML patients treated with intensive chemotherapy. Outcomes in patients with spliceosome mutations trea...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Adv
Auteurs principaux: Lachowiez, Curtis A., Loghavi, Sanam, Furudate, Ken, Montalban-Bravo, Guillermo, Maiti, Abhishek, Kadia, Tapan, Daver, Naval, Borthakur, Gautam, Pemmaraju, Naveen, Sasaki, Koji, Alvarado, Yesid, Yilmaz, Musa, Short, Nicholas J., Chien, Kelly, Ohanian, Maro, Pierce, Sherry, Patel, Keyur P., Jabbour, Elias, Ravandi, Farhad, Kantarjian, Hagop M., Garcia-Manero, Guillermo, Takahashi, Koichi, Konopleva, Marina Y., DiNardo, Courtney D.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2021
Sujets:
Myeloid Neoplasia
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8095152/
https://ncbi.nlm.nih.gov/pubmed/33885753
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020004173
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires